Investor Presentaiton

TIGIT Cluster: IBI-939 (TIGIT mAb) and IBI-321 (PD-1/TIGIT Bispecific Antibody) Development Plan Overview IBI-939 Preclinical Highlights • IBI-939 is fully human antibody with high TIGIT binding affinity and strong ligand blocking activity • • IBI-939 exhibited strong anti-tumor activities as monotherapy or in combination with anti-PD-1 antibody in different tumor models • IBI-939 Development Program Overview Clinical progress 2021 plan IBI-321 Preclinical Highlights Combining PD-1 and TIGIT inhibition to release PD-1/PD-L1 as well as TIGIT/PVR inhibition of intratumoral T/NK cells, to enhance T/NK-cell mediated anti-tumor efficacy Bridge PD-1 and TIGIT on the same cell (T cells, NK cells) to maximal activation of CD226/PVR and relieve tumor immunosuppression IBI-321 Development Program Overview Phase 1b study started • Phase 1 study started Clinical Started Phase 1b for IBI-939 in combination with sintilimab for advanced lung cancer in early 2021 progress Dosed the first patient of Phase 1 study for IBI-321 for advanced malignant tumors • Phase 1b study ongoing To keep enrolling Phase 1b for IBI-939 Phase 1 study ongoing 2021 plan To keep enrolling patients for the Phase 1 study of IBI-323 Leading and highly differentiated position in TIGIT area: TIGIT mAb under Phase 1b development; PD-1/TIGIT bispecifics started Phase 1 study with novel biological mechanism and potential strong synergy. Innovent Confidential Copyright©2021 Innovent Biologics 32

View entire presentation